DESTIN, Fla. — Adjustments made to the dosing and administration of immunomodulatory drugs may not have much impact on COVID-19 vaccine immunogenicity among patients with autoimmune and inflammatory rheumatic disease, according to data.
At a poster session presented at the Congress of Clinical Rheumatology East, Andrew Laster, MD, of the Arthritis & Osteoporosis Clinic of the Carolinas, stated that he and colleagues found that holding JAK inhibitors, lowering methotrexate dose or altering vaccine timing to accommodate rituximab or abatacept does not impact COVID-19 vaccine